Transmission rates and adaptive evolution of pathogens in sympatric heterogeneous plant populations.

Por Gudelj, I., van den Bosch, F., Gilligan, C. A.
Publicado em 2004

Disease control and its selection for damaging plant virus strains in vegetatively propagated staple food crops; a theoretical assessment

Por van den Bosch, F, Jeger, M.J, Gilligan, C.A
Publicado em 2006

Identifying circumstances under which high insecticide dose increases or decreases resistance selection

Por Helps, J.C., Paveley, N.D., van den Bosch, F.
Publicado no J Theor Biol (2017)

Dose and number of applications that maximize fungicide effective life exemplified by Zymoseptoria tritici on wheat – a model analysis

Por van den Berg, F., Paveley, N. D., van den Bosch, F.
Publicado no Plant Pathol (2016)

Cassava brown streak disease and the sustainability of a clean seed system

Por McQuaid, C. F., Sseruwagi, P., Pariyo, A., van den Bosch, F.
Publicado no Plant Pathol (2015)

Early detection surveillance for an emerging plant pathogen: a rule of thumb to predict prevalence at first discovery

Por Parnell, S., Gottwald, T. R., Cunniffe, N. J., Alonso Chavez, V., van den Bosch, F.
Publicado no Proc Biol Sci (2015)

Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo

Por Cruyssen, B Vander, De Keyser, F, Kruithof, E, Mielants, H, Van den Bosch, F
Publicado em 2007

Evolutionary bi-stability in pathogen transmission mode

Por van den Bosch, F., Fraaije, B. A., van den Berg, F., Shaw, M. W.
Publicado em 2010

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study

Por Van den Bosch, F., Kruithof, E., Baeten, D., De Keyser, F., Mielants, H., Veys, E.
Publicado em 2000

Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor α

Por Van den Bosch, F, Baeten, D, Kruithof, E, De Keyser, F, Mielants, H, Veys, E
Publicado em 2001

Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy

Por Kruithof, E, Baeten, D, Van den Bosch, F, Mielants, H, Veys, E, De Keyser, F
Publicado em 2005

The effect of infliximab on skin lesions in a patient with scleroderma (CREST)

Por De Rycke, L, Baeten, D, Van den Bosch, F, Mielants, H, De Keyser, F, Veys, EM
Publicado em 2004

Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up

Por Kruithof, E, Van den Bosch, F, Baeten, D, Herssens, A, De Keyser, F, Mielants, H, Veys, E
Publicado em 2002

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

Por De Rycke, L, Verhelst, X, Kruithof, E, Van den Bosch, F, Hoffman, I, Veys, E, De Keyser, F
Publicado em 2005

Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis

Por Kruithof, E, Kestelyn, P, Elewaut, C, Elewaut, D, Van den Bosch, F, Mielants, H, Veys, E, De Keyser, F
Publicado em 2002

Changes in rheumatoid factor reflect the inflammatory response (CRP and ESR) to infliximab treatment

Por De Rycke, L, Kruithof, E, Van Damme, N, Hoffman, IEA, Van den Bosch, F, Veys, EM, De Keyser, F
Publicado em 2003

Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα

Por Baeten, D, Van Damme, N, Van den Bosch, F, Kruithof, E, De Vos, M, Mielants, H, Veys, E, De Keyser, F
Publicado em 2001

Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the d...

Por Baeten, D, Kruithof, E, Van den Bosch, F, Van den Bossche, N, Herssens, A, Mielants, H, De Keyser, F, Veys, E
Publicado em 2003

Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity

Por Baeten, D, Demetter, P, Cuvelier, C, Van den Bosch, F, Kruithof, E, Van Damme, N, Verbruggen, G, Mielants, H, Veys, E, De Keyser, F
Publicado em 2000

Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheu...

Por Baeten, D, Houbiers, J, Kruithof, E, Vandooren, B, Van den Bosch, F, Boots, A M, Veys, E M, Miltenburg, A M M, De Keyser, F
Publicado em 2006